Search / Trial NCT06613139

Bioequivalence Study Between YHP2305 and YHR2404 in Healthy Volunteers

Launched by YUHAN CORPORATION · Sep 24, 2024

Trial Information

Current as of October 07, 2024

Recruiting

Keywords

Pharmacokinetics Bioequivalence

Description

Subjects in group A will be administered comparator and YHP2305 by crossover design on day 1, 8. Subjects in group B will be administered YHP2305 and comparator by crossover design on day 1, 8.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Those who are 19 years old or older at the screening visit
  • * Those whose weight is over 50kg(male), over 45kg(female) and their body mass index (BMI) shall be between 18.0 kg/m2 and 30.0 kg/m2
  • * Those who express their voluntary consent to participate in the trial by signing a written consent
  • * Those who are judged eligible to participate in the trial by the principal investigator(or delegated investigators) after screening test
  • Exclusion Criteria:
  • * Those who have participated in a bioequivalence study or other clinical trials and have been administered with investigational products in 6 months prior to the first administration.
  • * Others who are judged ineligible to participate in the trial by the principal investigator.

About Yuhan Corporation

Yuhan Corporation is a leading South Korean pharmaceutical company dedicated to the research, development, manufacturing, and marketing of innovative healthcare solutions. Established in 1926, Yuhan has a robust portfolio that includes prescription medications, over-the-counter products, and biologics, with a strong emphasis on oncology, infectious diseases, and central nervous system disorders. The company is committed to advancing medical science through strategic partnerships, cutting-edge research, and clinical trials aimed at bringing novel therapies to market. Yuhan's dedication to quality and excellence positions it as a prominent player in the global pharmaceutical landscape.

Locations

Seoul, , Korea, Republic Of

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0